title: The effect of pentoxifylline and its metabolite-1 on inflammation and fibrosis in the TNBS model of colitis.
abstract: TNBS-induced colitis has characteristics resembling human Crohn's disease including transmural inflammation, ulceration, and fibrosis. Current treatments target acute symptoms but do not necessarily prevent fibrotic complications of the disease. The aim of this study was to determine the effect of pentoxifylline and its primary metabolite (M-1) on fibrosis in the TNBS-induced colitis model. Myeloperoxidase activity and interleukin-18 are indicators of inflammation and were elevated in the TNBS model. The morphology damage score assesses colon damage and was also elevated in the TNBS model. Collagen as the indicator of fibrosis was quantified and visualized by the Sirius Red/Fast Green staining technique and collagen type I was assessed by Western analysis. Collagen was elevated in the TNBS-induced model. Pentoxifylline and M-1 treatment significantly attenuated colon damage and inflammation in TNBS-colitis (P<0.05). M-1 treatment significantly reduced the TNBS-induced increase in colon weight, colon thickness and total collagen content (P<0.05). Results suggest that pentoxifylline and M-1 inhibit intestinal fibrosis in this experimental model and may prove beneficial in the treatment of intestinal fibrosis associated with human Crohn's disease with the added benefit of inhibiting inflammation and ulceration. This is the first study to examine the effects of racemic M-1 in vivo and one of the few studies to examine the effect of drugs on both inflammation and fibrosis in an experimental model of colitis.
authors.affiliation: Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. tcpmed@dal.ca
authors.forename: Theresa C
authors.initials: TC
authors.lastname: Peterson
authors.forename: Marc R
authors.initials: MR
authors.lastname: Peterson
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Raoul
mesh_terms: D000818:Animals; D003092:Colitis / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D024042:Collagen Type I / Q000378:metabolism; D003106:Colon / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D005260:Female; D005355:Fibrosis; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D020382:Interleukin-18 / Q000378:metabolism; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D010431:Pentoxifylline / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology* / Q000627:therapeutic use; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013237:Stereoisomerism; D013997:Time Factors; D014302:Trinitrobenzenesulfonic Acid / Q000494:pharmacology*
chemical_list: D024042:Collagen Type I; D020382:Interleukin-18; D014302:Trinitrobenzenesulfonic Acid; D009195:Peroxidase; D010431:Pentoxifylline